TABLE 2.
Summary of analyses of significant effects of patient covariates tested alone in CL
| Hypothesis | Parameterization (CL/F) | Null value | θ4 (95% CI) | Change in objective function | P |
|---|---|---|---|---|---|
| Model 1 (do the following affect CL/F?) | |||||
| CD4 < 100 cells per μl | θ1(1 − θ4 · cd4) | 0 | 0.19 (0.02, 0.36) | 10.014 | <0.01 |
| Concomitant medications | |||||
| Fluconazole | θ1(1 − θ4 · flu) | 0 | 0.26 (0.11, 0.40) | 17.225 | <0.01 |
| Macrolide | θ1(1 − θ4 · mac)a | 0 | 0.24 (0.02, 0.46) | 10.784 | <0.01 |
| Ribabutin | θ1(1 + θ4 · rif)b | 0 | 0.55 (0.32, 0.77) | 6.035 | <0.05 |
| Model 2 (do the following affect CL/F?) | |||||
| CD4 < 100 cells per μl | θ1(1 − θ4 · cd4) | 0 | 0.17 (0.01, 0.33) | 6.978 | <0.01 |
| Concomitant medications | |||||
| Fluconazole | θ1(1 − θ4 · flu) | 0 | 0.27 (0.15, 0.40) | 18.531 | <0.01 |
| Macrolide | θ1(1 − θ4 · mac) | 0 | 0.23 (0.06, 0.41) | 10.132 | <0.01 |
| Rifabutin | θ1(1 + θ4 · rif) | 0 | 0.37 (0.17, 0.57) | 3.012 | Not significant |
a
mac, value of 1 for concomitant macrolide therapy and 0 otherwise.
b
rif, value of 1 for concomitant rifabutin therapy and 0 otherwise.